10x Genomics, Inc. (TXG) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
10x Genomics, Inc. (TXG) stock forecast summary
Our AI ranks 10x Genomics, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
10x Genomics, Inc. is a mid-cap company with a market capitalization of $9.10B. It ranks number 8 by market capitalization among the 25 Laboratory Analytical Instruments issuers in our coverage with a current forecast. Its Gross Margin of 70.0% is the highest of the 19 peers that report one.
For TXG, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 58.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 54.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, TXG included.
Follow TXG freeTXG price chart and AI forecast
How TXG ranks among 5172 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
10x Genomics, Inc. (TXG) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Laboratory Analytical Instruments peers listed below that report each metric.
Valuation & Market
| Metric | TXG | Rank |
|---|---|---|
| Market Cap | $9.10B | 8/25 |
| P/B Ratio | 11.03x | 3/23 |
| EPS | $-0.49 | – |
| Book Value/Share | $6.34 | – |
| Revenue/Share | $4.73 | – |
| FCF/Share | $0.93 | – |
Profitability & Margins
| Metric | TXG | Rank |
|---|---|---|
| ROE | -9.1% | 8/20 |
| ROA | -7.3% | 9/20 |
| ROIC | -9.7% | 10/20 |
| Gross Margin | 70.0% | 1/19 |
| Operating Margin | -14.3% | 11/21 |
| Net Margin | -12.2% | 8/19 |
| EBT Margin | -12.1% | 12/22 |
| Tax Rate | -0.3% | – |
Financial Health
| Metric | TXG | Rank |
|---|---|---|
| Current Ratio | 5.69x | 6/25 |
| Quick Ratio | 5.25x | 5/24 |
| D/E Ratio | 0.25x | 19/24 |
| Financial Leverage | 1.25x | 19/23 |
| Interest Coverage | -6898.5x | 21/21 |
| Working Capital | $556M | 8/25 |
Cash Flow
| Metric | TXG | Rank |
|---|---|---|
| Operating Cash Flow | $127M | 9/24 |
| Free Cash Flow | $121M | 7/20 |
| Capital Spending | -$6M | 12/20 |
| OCF Growth YoY | 89.8% | 1/12 |
| FCF Growth YoY | 113.5% | 1/11 |
| FCF/Sales | 19.7% | 3/19 |
| CapEx/Sales | 0.9% | 18/19 |
Operational Efficiency
| Metric | TXG | Rank |
|---|---|---|
| Asset Turnover | 0.60x | 7/20 |
| Receivables Turnover | 13.0x | 1/19 |
| Inventory Turnover | 3.5x | 4/19 |
| Fixed Assets Turnover | 2.9x | 18/21 |
| Days Sales Outstanding | 28 days | 19/19 |
| Days Inventory | 104 days | 16/19 |
| Payables Period | 41 days | 12/18 |
| Cash Conversion Cycle | 91 days | 15/17 |
Income Statement
| Metric | TXG | Rank |
|---|---|---|
| Total Revenue | $617M | 9/21 |
| Operating Income | -$88M | 17/21 |
| Net Income | -$75M | 15/21 |
| R&D Expense | $227M | 7/21 |
| SG&A Expense | $297M | 9/20 |
| Cost of Goods Sold | $185M | 8/19 |
Dividend & Shareholder Information
| Metric | TXG | Rank |
|---|---|---|
| Shares Outstanding | 130M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $675M | 65.5% of assets |
| Cash & Short-term Investments | $503M | 48.8% of assets |
| Accounts Receivable | $48M | 4.6% of assets |
| Inventory | $53M | 5.1% of assets |
| Total Liabilities | $205M | 19.9% of assets |
| Short-term Debt | $98M | 9.5% of assets |
TXG quarterly financials and insider trading
10x Genomics, Inc. (TXG) industry peers
Companies classified under the same SEC industry code as 10x Genomics, Inc. (Laboratory Analytical Instruments): 25 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| TXG 10x Genomics, Inc. | ▲ | $9.10B |
| A Agilent Technologies, Inc. | ▼ | $48.77B |
| WAT Waters Corp /De/ | ▶ | $42.93B |
| ILMN Illumina, Inc. | ▲ | $39.64B |
| MTD Mettler Toledo International Inc/ | ▼ | $32.51B |
| RVTY Revvity, Inc. | ▶ | $17.03B |
| AVTR Avantor, Inc. | ▼ | $11.19B |
| BIO Bio-Rad Laboratories, Inc. | ▶ | $9.46B |
| BRKR Bruker Corp | ▲ | $8.35B |
| ALMR Alamar Biosciences, Inc. | ▲ | $1.75B |
| CTKB Cytek Biosciences, Inc. | ▲ | $682M |
| PACB Pacific Biosciences Of California, Inc. | ▲ | $538M |
| MASS 908 Devices Inc. | ▲ | $465M |
| NAUT Nautilus Biotechnology, Inc. | ▲ | $262M |
| EYPT Eyepoint, Inc. | ▲ | $258M |
| BFNH Bioforce Nanosciences Holdings, Inc. | ▼ | $235M |
| QTRX Quanterix Corp | ▲ | $136M |
| SEER Seer, Inc. | ▲ | $112M |
| RPID Rapid Micro Biosystems, Inc. | ▲ | $38M |
| PRPO Precipio, Inc. | ▲ | $38M |
| HBIO Harvard Bioscience Inc | ▼ | $37M |
| BNGO Bionano Genomics, Inc. | ▲ | $15M |
| LCTC Lifeloc Technologies, Inc | ▲ | $11M |
| ASTC Astrotech Corp | ▶ | $10M |
| SCND Scientific Industries Inc | ▲ | $8M |
Where TXG sits on the market map
10x Genomics, Inc. (TXG) stock news
Loading...
10x Genomics, Inc. (TXG) stock forecast FAQ
What is the 10x Genomics, Inc. (TXG) stock forecast?
Our AI ranks 10x Genomics, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are 10x Genomics, Inc. stock predictions?
For TXG, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 58.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 54.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are 10x Genomics, Inc. forecasts updated?
10x Genomics, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are 10x Genomics, Inc.'s industry peers?
25 issuers in our coverage, TXG included, share the SEC industry code Laboratory Analytical Instruments. The largest are: Agilent Technologies, Inc. (A), Waters Corp /De/ (WAT), Illumina, Inc. (ILMN), Mettler Toledo International Inc/ (MTD), Revvity, Inc. (RVTY), Avantor, Inc. (AVTR).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.